GlassScriptPhysician profile
Marla R Capes
NPI 1346644572
$3,894.15
in general payments reported to CMS, 2019-2025
35 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $433 · 2022: $334 · 2023: $771 · 2024: $1,043 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,127.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $511.61 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $446.96 | 2021-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $337.97 | 2022-2025 | |
| Abbvie INC. | $316.37 | 2022-2025 | |
| Lilly USA, LLC | $299.97 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $289.86 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $221.78 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.56 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $178.04 | 2021-2025 | Airsupra, Fasenra, Bevespi Aerosphere |
| Exact Sciences Corporation | $141.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $123.30 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Axsome Therapeutics, INC. | $85.36 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $83.81 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $49.12 | 2025 | Gemtesa |
| Dynavax Technologies Corporation | $48.12 | 2024-2025 | Heplisav-B |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Capes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.